Publicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (22)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Comparison of three PCR-based methods to detect Loa loa and Mansonella perstans in long-term frozen storage dried blood spots

    Tropical Medicine and International Health, Vol. 27, Núm. 8, pp. 686-695

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2019

  1. Comparative genomics of the major parasitic worms

    Nature Genetics, Vol. 51, Núm. 1, pp. 163-174

2017

  1. Neoflavonoids as inhibitors of HIV-1 replication by targeting the Tat and NF-κB pathways

    Molecules, Vol. 22, Núm. 2

2015

  1. A survey of intestinal parasites including associated risk factors in humans in Panama

    Acta Tropica, Vol. 147, pp. 54-63

2014

  1. A Fasciola hepatica-derived fatty acid binding protein induces protection against schistosomiasis caused by Schistosoma bovis using the adjuvant adaptation (ADAD) vaccination system

    Experimental Parasitology, Vol. 145, Núm. 1, pp. 145-151

2012

  1. Adaptive immune stimulation is required to obtain high protection with fatty acid binding protein vaccine candidate against fasciola hepatica in balb/C mice

    Journal of Parasitology, Vol. 98, Núm. 3, pp. 527-535

2011

  1. Antimalarial activity of imidazo[2,1-a]isoindol-5-ol derivatives and related compounds

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 11, pp. 5379-5386

2009

  1. Trichinella: Differential expression of angiogenic factors in macrophages stimulated with antigens from encapsulated and non-encapsulated species

    Experimental Parasitology, Vol. 123, Núm. 4, pp. 347-353

2008

  1. The addition of a new immunomodulator with the adjuvant adaptation ADAD system using fatty acid binding proteins increases the protection against Fasciola hepatica

    Veterinary Parasitology, Vol. 153, Núm. 1-2, pp. 176-181

2007

  1. Genetic and immunological characterization of the 14-3-3ζ molecule from Schistosoma bovis

    Journal of Parasitology, Vol. 93, Núm. 4, pp. 964-969

  2. Identification of Fasciola hepatica recombinant 15-KDA fatty acid-binding protein T-cell epitopes that protect against experimental fascioliasis in rabbits and mice

    Journal of Parasitology, Vol. 93, Núm. 4, pp. 817-823

  3. Immunomodulation of the response to excretory/secretory antigens of Fasciola hepatica by anapsos® in Balb/C mice and rat alveolar macrophages

    Journal of Parasitology, Vol. 93, Núm. 2, pp. 428-432

  4. Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD

    Veterinary Parasitology, Vol. 145, Núm. 3-4, pp. 287-296

  5. The Sb14-3-3ζ recombinant protein protects against Schistosoma bovis in BALB/c mice

    Vaccine, Vol. 25, Núm. 23, pp. 4533-4539

  6. The Schistosoma bovis Sb14-3-3ζ recombinant protein cross-protects against Schistosoma mansoni in BALB/c mice

    Vaccine, Vol. 25, Núm. 41, pp. 7217-7223

  7. Trichinella: Differing effects of antigens from encapsulated and non-encapsulated species on in vitro nitric oxide production

    Veterinary Parasitology, Vol. 143, Núm. 1, pp. 86-90

2006

  1. Synthesis and evaluation of some lipidic aminoalcohols and diamines as immunomodulators

    Bioorganic and Medicinal Chemistry Letters, Vol. 16, Núm. 23, pp. 6091-6095